A British study published Wednesday, June 16 shows the antibody cocktail being developed by Regeneron Pharmaceuticals’ reduces COVID-19 deaths in hospitalized patients who have not mounted their own antibody response. But as for AstraZeneca, the company says a late-stage trial failed to provide evidence its COVID-19 antibody therapy protected people who had contact with an infected person from the disease.
Related stories:
https://www.rappler.com/science/life-health/regeneron-covid-19-therapy-cuts-deaths-hospitalized-patients-lack-antibodies-study
https://www.rappler.com/science/life-health/astrazeneca-antibody-cocktail-fails-prevent-covid-19-symptoms-trial
